Paracel Explorer

Dernière publication·Juillet 2026

Sandostatine

Octreotidum — sol inj 0.5 mg/ml

Novartis Pharma Schweiz AG

Swissmedic49137

Dossier15538

Statut

Original

GénériquesOctreotid Labatec

Remboursement

QP 10%

Modifications (6)